|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 112.54 USD | -2.15% |
|
+2.80% | +5.03% |
| 05-21 | Ligand Pharmaceuticals Incorporated, Q1 2025 Earnings Call, May 08, 2025 | |
| 05-20 | Ligand Pharmaceuticals Pick of the Week at Smart Insider Following CEO, CFO Stock Purchases | MT |
| Capitalization | 2.17B 1.88B 1.77B 1.61B 2.95B 187B 3.34B 20.65B 8.06B 85.66B 8.15B 7.97B 315B | P/E ratio 2025 * |
-
| P/E ratio 2026 * | 27.3x |
|---|---|---|---|---|---|
| Enterprise value | 2.17B 1.88B 1.77B 1.61B 2.95B 187B 3.34B 20.65B 8.06B 85.66B 8.15B 7.97B 315B | EV / Sales 2025 * |
11.2x | EV / Sales 2026 * | 9.42x |
| Free-Float |
98.11% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Ligand Pharmaceuticals Incorporated
More recommendations
More press releases
More news
| 1 day | -2.15% | ||
| 1 week | +2.80% | ||
| Current month | +10.13% | ||
| 1 month | +7.65% | ||
| 3 months | +2.36% | ||
| 6 months | -8.01% | ||
| Current year | +5.03% |
| 1 week | 106.3 |  | 116.4 |
| 1 month | 98.89 | | 116.4 |
| Current year | 93.58 | | 125.17 |
| 1 year | 77.53 | | 129.9 |
| 3 years | 49.24 | | 129.9 |
| 5 years | 49.24 | | 219.75 |
| 10 years | 49.24 | | 278.62 |
| Manager | Title | Age | Since |
|---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 65 | 04/12/2022 |
| Director of Finance/CFO | 46 | 20/05/2015 | |
Octavio Espinoza
DFI | Director of Finance/CFO | 55 | 31/10/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
John Kozarich
CHM | Chairman | 75 | 28/02/2003 |
Jason Aryeh
BRD | Director/Board Member | 57 | 26/09/2006 |
Todd Davis
BRD | Director/Board Member | 65 | 28/02/2007 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 0.24% | 23 M€ | -8.92% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.15% | +2.80% | +39.56% | +48.31% | 2.17B | ||
| -2.02% | +2.27% | -10.60% | +174.67% | 710B | ||
| -1.83% | -1.84% | +4.41% | -10.41% | 367B | ||
| -2.03% | -6.12% | -50.23% | +31.32% | 335B | ||
| -2.82% | -1.95% | +9.31% | +33.30% | 328B | ||
| -0.49% | -3.04% | +6.56% | -13.81% | 258B | ||
| -0.83% | -2.05% | +2.17% | +20.65% | 230B | ||
| -1.44% | -1.02% | -14.21% | +9.24% | 223B | ||
| -3.31% | -1.32% | -38.60% | -7.79% | 197B | ||
| -1.86% | +0.02% | -4.36% | +25.72% | 156B | ||
| Average | -0.80% | -1.36% | -5.60% | +31.12% | 280.47B | |
| Weighted average by Cap. | -0.46% | -0.45% | -10.28% | +52.58% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 194M 168M 158M 144M 264M 16.75B 298M 1.85B 720M 7.65B 728M 713M 28.15B | 231M 200M 188M 171M 314M 19.91B 355M 2.19B 856M 9.1B 865M 847M 33.46B |
| Net income | -274K -238K -223K -203K -372K -23.64M -421K -2.6M -1.02M -10.8M -1.03M -1.01M -39.72M | 81.33M 70.57M 66.23M 60.25M 111M 7.02B 125M 773M 302M 3.21B 305M 299M 11.8B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
68
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/06/25 | 112.54 $ | -2.15% | 123,652 |
| 16/06/25 | 115.01 $ | +2.23% | 96,488 |
| 13/06/25 | 112.50 $ | -1.70% | 83,335 |
| 12/06/25 | 114.45 $ | -0.81% | 121,715 |
| 11/06/25 | 115.39 $ | +1.74% | 183,834 |
Delayed Quote Nasdaq, June 17, 2025 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
112.54USD
Average target price
143.88USD
Spread / Average Target
+27.84%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LGND Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition